Mangoceuticals (NASDAQ:MGRX – Get Free Report) is one of 19 public companies in the “Miscellaneous health & allied services, not elsewhere classified” industry, but how does it compare to its competitors? We will compare Mangoceuticals to related companies based on the strength of its analyst recommendations, dividends, institutional ownership, valuation, risk, profitability and earnings.
Profitability
This table compares Mangoceuticals and its competitors’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Mangoceuticals | -1,053.93% | -243.34% | -200.73% |
Mangoceuticals Competitors | -816.62% | -48.14% | -36.60% |
Volatility & Risk
Mangoceuticals has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500. Comparatively, Mangoceuticals’ competitors have a beta of 4.14, meaning that their average stock price is 314% more volatile than the S&P 500.
Valuation & Earnings
Gross Revenue | Net Income | Price/Earnings Ratio | |
Mangoceuticals | $866,792.00 | -$9.21 million | -0.38 |
Mangoceuticals Competitors | $2.39 billion | $82.32 million | 15.54 |
Mangoceuticals’ competitors have higher revenue and earnings than Mangoceuticals. Mangoceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
56.7% of Mangoceuticals shares are owned by institutional investors. Comparatively, 61.8% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are owned by institutional investors. 39.3% of Mangoceuticals shares are owned by insiders. Comparatively, 27.3% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Mangoceuticals and its competitors, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Mangoceuticals | 0 | 0 | 0 | 0 | N/A |
Mangoceuticals Competitors | 36 | 288 | 416 | 148 | 2.76 |
As a group, “Miscellaneous health & allied services, not elsewhere classified” companies have a potential upside of 50.46%. Given Mangoceuticals’ competitors higher possible upside, analysts clearly believe Mangoceuticals has less favorable growth aspects than its competitors.
Summary
Mangoceuticals competitors beat Mangoceuticals on 9 of the 10 factors compared.
About Mangoceuticals
Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.
Receive News & Ratings for Mangoceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mangoceuticals and related companies with MarketBeat.com's FREE daily email newsletter.